In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes
<p><strong>Question:</strong><br /> In patients with type 2 diabetes, do sodium–glucose cotransporter-2 (SGLT-2) inhibitors reduce risk for major kidney outcomes?</p><br /> <p><strong>Review Methods:</strong><br /> MEDLINE and Embase searc...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American College of Physicians
2020
|